Opportunity Information: Apply for PAR 21 348
This grant opportunity (PAR-21-348) from the National Institutes of Health supports research on how Epstein-Barr virus (EBV) contributes to the development of Non-Hodgkin Lymphoma (NHL) and Hodgkin disease (HD), both in people living with HIV/AIDS and in people without HIV. The main goal is to deepen scientific understanding of the mechanisms and real-world patterns linking EBV infection to lymphoma initiation, progression, and downstream health effects. The funding announcement is intentionally broad about research approaches, encouraging mechanistic, epidemiological, and translational studies that can clarify how EBV drives or accelerates lymphomagenesis, how disease evolves over time, and what biological or clinical sequelae result from EBV-associated lymphoma.
A central emphasis is comparing EBV-related lymphoma biology in HIV-positive versus HIV-negative populations. Because HIV alters immune surveillance and the tumor microenvironment, EBV may behave differently depending on HIV status, including differences in viral latency programs, immune evasion strategies, inflammatory signaling, and host-pathogen interactions that shape lymphoma risk and outcomes. Projects responsive to this opportunity would typically aim to identify pathways and markers that explain why certain EBV-infected individuals progress to NHL or HD, how EBV affects tumor behavior, and what factors determine differences in incidence, aggressiveness, or treatment response across HIV-stratified groups. Studies may also address how EBV-associated lymphomas emerge and persist under immune suppression, and how that compares to EBV-driven disease in immunocompetent settings.
The award mechanism is a U01 cooperative agreement, meaning funded projects are expected to involve substantial NIH scientific or programmatic involvement compared with a standard research project grant. While clinical trials are optional, the announcement allows them, so applicants can propose interventional studies if they are well-justified and aligned with the scientific aims. In practice, this structure is often used for complex, collaborative, or multi-component research efforts where coordination, harmonized methods, or shared infrastructure (such as cohorts, biorepositories, standardized assays, or multi-site data collection) can strengthen the work and improve comparability across studies.
Eligibility is broad and includes many types of domestic organizations: state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations not federally recognized; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (excluding higher education where specified); for-profit organizations (other than small businesses); and small businesses. The announcement also explicitly highlights additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and non-U.S. entities (foreign organizations). This broad eligibility signals an interest in diverse applicant pools, including organizations positioned to study populations disproportionately affected by HIV, EBV, and lymphoma, or to conduct research in settings where disease burden and viral epidemiology may differ.
The opportunity is categorized as discretionary funding and falls under education and health-related funding activity categories, with CFDA numbers 93.393 and 93.395. The posting indicates an original closing date of 2023-12-15, with the announcement created on 2021-09-27. The award ceiling and expected number of awards are not specified in the provided source data, which typically means applicants must rely on the full notice and NIH institute-specific guidance to understand budget expectations, project period norms, and program priorities.
Overall, the program is aimed at producing clearer, evidence-backed answers about how EBV contributes to NHL and HD, what changes when HIV is present, and how those insights can translate into better risk stratification, prevention strategies, biomarkers, and potentially new therapeutic or clinical management approaches for EBV-associated lymphomas across different immune contexts.Apply for PAR 21 348
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "The role of Epstein Barr virus (EBV) infection in Non-Hodgkin Lymphoma (NHL) and Hodgkin disease (HD) development with or without an underlying HIV infection (U01 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393, 93.395.
- This funding opportunity was created on 2021-09-27.
- Applicants must submit their applications by 2023-12-15. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Browse more opportunities from the same category: Education, Health
Next opportunity: Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional)
Previous opportunity: Highlands Conservation Act Grant Program – Competitive Funding
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 21 348
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 21 348) also looked into and applied for these:
| Funding Opportunity |
|---|
| Limited Competition: Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium (U24 Clinical Trial Not Allowed) Apply for PAR 21 346 Funding Number: PAR 21 346 Agency: National Institutes of Health Category: Education, Health Funding Amount: $940,000 |
| Exploratory Grants in Cancer Control (R21 Clinical Trial Optional) Apply for PAR 21 341 Funding Number: PAR 21 341 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NIH Health Care Systems Research Collaboratory - Pragmatic and Implementation Trials of Embedded Interventions (UG3/UH3, Clinical Trials Optional) Apply for RFA AT 22 001 Funding Number: RFA AT 22 001 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Clinical Research Education and Career Development (CRECD) Program (R25-Independent Clinical Trial Not Allowed) Apply for PAR 21 347 Funding Number: PAR 21 347 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed) Apply for PAR 22 049 Funding Number: PAR 22 049 Agency: National Institutes of Health Category: Education, Health Funding Amount: $250,000 |
| A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials (CUSP2CT; U01 Clinical Trial Optional) Apply for RFA CA 21 063 Funding Number: RFA CA 21 063 Agency: National Institutes of Health Category: Education, Health Funding Amount: $450,000 |
| Clinical Sites for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (UG1 Clinical Trial Required) Apply for RFA CA 21 047 Funding Number: RFA CA 21 047 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Coordinating Center for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (U24 Clinical Trial Required) Apply for RFA CA 21 045 Funding Number: RFA CA 21 045 Agency: National Institutes of Health Category: Education, Health Funding Amount: $750,000 |
| Research Bases for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (UG1 Clinical Trial Required) Apply for RFA CA 21 046 Funding Number: RFA CA 21 046 Agency: National Institutes of Health Category: Education, Health Funding Amount: $400,000 |
| Limited Competition: NIH Health Care Systems Research Collaboratory - Coordinating Center (U24 Clinical Trial Not Allowed) Apply for RFA AT 22 002 Funding Number: RFA AT 22 002 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| HEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness Research Network Cooperative Agreement (UG3/UH3, Clinical Trial Required) Apply for RFA AT 22 005 Funding Number: RFA AT 22 005 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| HEAL Initiative: Pragmatic and Implementation Studies for the Management of Sickle Cell Disease Pain (UG3/UH3, Clinical Trials Optional) Apply for RFA AT 22 004 Funding Number: RFA AT 22 004 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R21 Clinical Trial Not Allowed) Apply for PAR 22 062 Funding Number: PAR 22 062 Agency: National Institutes of Health Category: Education, Health Funding Amount: $275,000 |
| Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R01 Clinical Trial Not Allowed) Apply for PAR 22 061 Funding Number: PAR 22 061 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) Apply for RFA CA 22 003 Funding Number: RFA CA 22 003 Agency: National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) Apply for RFA CA 22 004 Funding Number: RFA CA 22 004 Agency: National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required) Apply for RFA CA 21 062 Funding Number: RFA CA 21 062 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required) Apply for RFA CA 21 061 Funding Number: RFA CA 21 061 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed) Apply for RFA CA 21 060 Funding Number: RFA CA 21 060 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NIH HEAL Initiative: Preventing Opioid Misuse and Co-Occurring Conditions by Intervening on Social Determinants (R01 Clinical Trials Optional) Apply for RFA DA 22 036 Funding Number: RFA DA 22 036 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 21 348", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.